Recent discussions on X about AstraZeneca (AZN) have been buzzing with reactions to the company’s latest quarterly earnings report, which surpassed expectations with an EPS of $2.17 against a forecast of $1.09 and revenue of $14.46 billion compared to an estimated $14.09 billion. Many users are highlighting the company’s strong performance in the U.S. and oncology sectors as key drivers of this growth, sparking renewed interest in the stock’s trajectory. The announcement of a $50 billion investment in U.S. manufacturing and R&D by 2030 has also fueled conversations about long-term potential.
While some on X express optimism about AstraZeneca’s strategic moves and robust financials, others are more cautious, pointing to external pressures like pricing challenges and trade uncertainties that could impact future gains. The dialogue reflects a mix of excitement over the record revenue and curiosity about how the massive U.S. investment will play out. Overall, the chatter underscores a pivotal moment for the pharmaceutical giant as it navigates both opportunity and risk.
Note: This discussion summary was generated from an AI condensation of post data.
AstraZeneca Congressional Stock Trading
Members of Congress have traded $AZN stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $AZN stock by members of Congress over the last 6 months:
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AstraZeneca Hedge Fund Activity
We have seen 594 institutional investors add shares of AstraZeneca stock to their portfolio, and 522 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FISHER ASSET MANAGEMENT, LLC added 9,205,607 shares (+84.0%) to their portfolio in Q1 2025, for an estimated $676,612,114
- BANK OF AMERICA CORP /DE/ added 7,806,049 shares (+32.5%) to their portfolio in Q1 2025, for an estimated $573,744,601
- CAPITAL INTERNATIONAL INVESTORS removed 6,221,599 shares (-16.6%) from their portfolio in Q1 2025, for an estimated $457,287,526
- JENNISON ASSOCIATES LLC removed 4,868,731 shares (-31.6%) from their portfolio in Q1 2025, for an estimated $357,851,728
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,265,092 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $239,984,262
- GOLDMAN SACHS GROUP INC added 3,259,351 shares (+31.4%) to their portfolio in Q1 2025, for an estimated $239,562,298
- D. E. SHAW & CO., INC. removed 3,128,538 shares (-64.8%) from their portfolio in Q1 2025, for an estimated $229,947,543
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AstraZeneca Government Contracts
We have seen $1,293,928 of award payments to $AZN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STRENSIQ: $1,253,969
- THIS PROJECT IS FOR PROCUREMENT OF STORAGE AND STABILITY STUDY OF LIVE ATTENUATED MASTER AND WORKING SEED L...: $39,959
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AstraZeneca Analyst Ratings
Wall Street analysts have issued reports on $AZN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 02/13/2025
To track analyst ratings and price targets for AstraZeneca, check out Quiver Quantitative's $AZN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
